← Back to Screener
Pulse Biosciences, Inc Common Stock (DE) (PLSE)
Price$20.51
Favorite Metrics
Price vs S&P 500 (26W)-5.47%
Price vs S&P 500 (4W)-18.55%
Market Capitalization$1.34B
All Metrics
Book Value / Share (Quarterly)$1.19
P/TBV (Annual)11.62x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-20.63%
Cash Flow / Share (Quarterly)$-0.80
Price vs S&P 500 (YTD)40.44%
Gross Margin (TTM)-54.00%
Net Profit Margin (TTM)-10519.43%
EPS (TTM)$-1.08
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-1.08
EPS (Annual)$-1.08
ROI (Annual)-90.24%
Gross Margin (Annual)-54.00%
Net Profit Margin (5Y Avg)-12111.99%
Cash / Share (Quarterly)$1.19
ROA (Last FY)-76.99%
EBITD / Share (TTM)$-1.14
ROE (5Y Avg)-125.64%
Operating Margin (TTM)-11034.29%
Cash Flow / Share (Annual)$-0.80
P/B Ratio16.56x
P/B Ratio (Quarterly)11.54x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3585.46x
Net Interest Coverage (TTM)-129.02x
ROA (TTM)-63.71%
EPS Incl Extra (Annual)$-1.08
Current Ratio (Annual)10.53x
Quick Ratio (Quarterly)10.22x
3-Month Avg Trading Volume0.30M
52-Week Price Return18.77%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.18
P/S Ratio (Annual)3816.13x
Asset Turnover (Annual)0.00x
52-Week High$26.30
Operating Margin (5Y Avg)-12131.87%
EPS Excl Extra (Annual)$-1.08
CapEx CAGR (5Y)-5.31%
Tangible BV CAGR (5Y)25.05%
26-Week Price Return-1.48%
Quick Ratio (Annual)10.22x
13-Week Price Return34.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.53x
Enterprise Value$1,254.91
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-4.23%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.10x
Pretax Margin (Annual)-20794.57%
Cash / Share (Annual)$1.19
3-Month Return Std Dev129.07%
Net Income / Employee (TTM)$-1
ROE (Last FY)-90.24%
Net Interest Coverage (Annual)-51.91x
EPS Basic Excl Extra (Annual)$-1.08
Receivables Turnover (TTM)23.33x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.08
Receivables Turnover (Annual)22.95x
ROI (TTM)-73.46%
P/S Ratio (TTM)3816.13x
Pretax Margin (5Y Avg)-12111.99%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$1.18
Price vs S&P 500 (52W)-11.06%
Year-to-Date Return43.08%
5-Day Price Return2.05%
EPS Normalized (Annual)$-1.08
ROA (5Y Avg)-76.26%
Net Profit Margin (Annual)-20794.57%
Month-to-Date Return-9.01%
Cash Flow / Share (TTM)$-0.90
EBITD / Share (Annual)$-1.14
Operating Margin (Annual)-21982.57%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-125.20%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.08
P/TBV (Quarterly)11.62x
P/B Ratio (Annual)11.54x
Inventory Turnover (TTM)4.10x
Pretax Margin (TTM)-10519.43%
Book Value / Share (Annual)$1.19
Price vs S&P 500 (13W)34.14%
Beta1.67x
Revenue / Share (TTM)$0.01
ROE (TTM)-73.46%
52-Week Low$12.56
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.25
4.25
4.25
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PLSEPulse Biosciences, Inc Common Stock (DE) | 3816.13x | — | -54.00% | -11034.29% | $20.51 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Pulse Biosciences develops Nano-Pulse Stimulation (NPS), a proprietary bioelectric medicine technology that uses precise nanosecond electrical pulses to remove diseased cells while preserving surrounding healthy tissue. The platform addresses multiple medical indications where current treatment options are insufficient or suboptimal. NPS represents a potentially transformative approach for treating conditions across various therapeutic areas.